| Tonia Lynne Peters, DO | |
|
1215 E Michigan Ave, Lansing, MI 48912-1811 | |
| (517) 364-5610 | |
| Not Available |
| Full Name | Tonia Lynne Peters |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 1215 E Michigan Ave, Lansing, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174182786 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 5151013624 (Michigan) | Primary |
| Entity Name | Lilac Healthcare Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730724477 PECOS PAC ID: 7911333596 Enrollment ID: O20200129002347 |
News Archive
In the November 1st issue of G&D, a team of scientists led by Dr. Anil Rustgi (UPENN) presents an innovative new model of esophageal cancer, which holds great promise as an experimental platform to investigate the etiology and possible treatment of this devastating disease.
Eddingpharm continued to aggressively build its product portfolio by inking another cancer agreement, this time with Immutep. In this latest agreement, Eddingpharm was granted exclusive rights to develop and market ImmuFact® IMP321 in mainland China, Hong Kong, Macau, and Taiwan.
Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA platform to develop targeted autoimmune disease treatments, today announced that it will present at the 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and 15th Annual Conference of Rehabilitation in MS in Gothenburg, Sweden, data from its concluded Phase 2 clinical trial showing that baseline blood plasma anti-MBP (myelin basic protein) profiles identify responders to BHT-3009 treatment.
Wellcome Trust Sanger Institute scientists show how the parasite responsible for the neglected tropical disease Black Fever (visceral leishmaniasis) can become resistant to drug treatment. Studying the whole genomes of more than 200 samples of Leishmania donovani revealed that the addition of just two bases of DNA to a gene known as LdAQP1 stops the parasite from absorbing antimonial drugs.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tonia Lynne Peters, DO 1215 E Michigan Ave, Lansing, MI 48912-1811 Ph: (517) 364-5610 | Tonia Lynne Peters, DO 1215 E Michigan Ave, Lansing, MI 48912-1811 Ph: (517) 364-5610 |
News Archive
In the November 1st issue of G&D, a team of scientists led by Dr. Anil Rustgi (UPENN) presents an innovative new model of esophageal cancer, which holds great promise as an experimental platform to investigate the etiology and possible treatment of this devastating disease.
Eddingpharm continued to aggressively build its product portfolio by inking another cancer agreement, this time with Immutep. In this latest agreement, Eddingpharm was granted exclusive rights to develop and market ImmuFact® IMP321 in mainland China, Hong Kong, Macau, and Taiwan.
Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA platform to develop targeted autoimmune disease treatments, today announced that it will present at the 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and 15th Annual Conference of Rehabilitation in MS in Gothenburg, Sweden, data from its concluded Phase 2 clinical trial showing that baseline blood plasma anti-MBP (myelin basic protein) profiles identify responders to BHT-3009 treatment.
Wellcome Trust Sanger Institute scientists show how the parasite responsible for the neglected tropical disease Black Fever (visceral leishmaniasis) can become resistant to drug treatment. Studying the whole genomes of more than 200 samples of Leishmania donovani revealed that the addition of just two bases of DNA to a gene known as LdAQP1 stops the parasite from absorbing antimonial drugs.
› Verified 8 days ago
Dr. Jessica Frost, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1215 E Michigan Ave, Lansing, MI 48912 Phone: 517-364-5610 | |
Laura Tate, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1215 E Michigan Ave, Lansing, MI 48912 Phone: 517-364-2570 | |
Dr. Alane Marie Laws-barker, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1100 W Saginaw St, Suite 630, Lansing, MI 48915 Phone: 517-364-6363 Fax: 517-364-6364 | |
Carla Formoso Pico, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1215 E Michigan Ave, Lansing, MI 48912 Phone: 517-364-1000 | |
Dr. Jeffrey C Stieve, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 206 E Michigan Ave, Lansing, MI 48933 Phone: 517-373-3197 | |
Katelyn Ann Smiles, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1215 E Michigan Ave, Lansing, MI 48912 Phone: 517-364-2577 | |
Mohammad Mohsenian, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1200 E Michigan Ave, Suite 305, Lansing, MI 48912 Phone: 517-484-4900 Fax: 517-484-4508 |